

CollPlant Holdings Ltd.
("the Company")

August 6th 2015.

To:
Israel Security Authority
www.isa.gov.il

To:
Tel Aviv Stock Exchange Ltd.
www.tase.co.il

Dear Sir/Madam,

RE: Approval of significant patent in Europe

The company is honored to announce that on August 5th 2015, CollPlant Ltd., a wholly owned subsidiary of the Company ("**CollPlant**"), has received approval for the registration of a patent in Europe. The patent protects the Company's methods for the production of functional Pro-Collagen,¹ which is extracted from plants, as well as use of this molecule for accelerating wound healing.²

The registration of the patent, number WO2009/128076, which is fully owned by CollPlant, has been approved under CollPlant's name in accordance with an application that was filed on April 16th 2009. The patent expires on May 23rd 2029.

The Company maintains patents registration for the methods and procedures which are part of its core business activity, as part of its strategy to protect the intellectual property of CollPlant and of the Company.

About CollPlant

CollPlant is a clinical-stage regenerative medicine company leveraging its proprietary, plant-based rhCollagen technology for the development and commercialization of tissue repair products, initially for the ortho-biologics and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary recombinant human collagen (rhCollagen), among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved bio-functionality, superior homogeneity and reduced risk of immune response. The

¹ Pro-collagen is a precursor molecule to collagen. After enzymatic processing for the removal of the edges the pro-collagen becomes collagen.

² For more information, see section 17.4.2 in Chapter A (Description of the Corporation's Affairs) of the Company's periodic report for 2014 dated March 22nd 2015 [reference no. 2015-01-057259].

Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Leading products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; Vergenix™FG (Flowable Gel) wound filler, for the treatment of acute and chronic wounds, and Vergenix™BVF (Bone Void Filler), for use in spinal fusion procedures and trauma. CollPlant's business strategy includes proprietary development and manufacturing of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products.

For more information about CollPlant, visit <http://www.collplant.com>

Respectfully,

CollPlant Holdings Ltd.

Signed in the name of the company by:

Yehiel Tal, Chief Executive Officer

Eran Rotem, Chief Finance Officer